|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transhepatic fibrinolysis of mesenteric and portal vein thrombosis in a patient with uIterative colitis: A case report显示文摘AIM: To present a case of acute mesenteric and portal vein thrombosis treated with thrombolytic therapy in a patient with ulcerative colitis in acute phase and to review the literature on thrombolytic therapy of mesenteric-portal system. Treatment of acute portal vein thrombosis has ranged from conservative treatment with thrombolysis and anticoagulation therapy to surgical treatment with thrombectomy and/or intestinal resection.METHODS: We treated our patient with intraportal infusion of plasminogen activator and then heparin through a percutaneous transhepatic catheter.RESULTS: Thrombus resolved despite premature interruption of the thrombolytic treatment for neurological complications, which subsequently resolved.CONCLUSION: Conservative management with plasminogen activator, could be considered as a good treatment for patients with acute porto-mesenteric thrombosis. | Alfredo Guglielmi Francesca Fior Orsolya Halmos Gian Franco Veraldi Lorenzo Rossaro Andrea Ruzzenente Claudio Cordiano | 2005 | World Journal of Gastroenterology2005，11，13： | 3 |
| 2 | Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents显示文摘AIM To evaluate the outcomes in biological treatment and quality of life of psoriatic patients with chronic hepatitis C(CHC) treated with new Direct-Acting Antiviral agents(DAAs) compared to pegylated interferon-2α plus ribavirin(P/R) therapy.METHODS This is a retrospective study involving psoriatic patients in biological therapy who underwent anti-hepatitis C virus(HCV) treatment at the Department of Dermatology Galeazzi Orthopaedic Institute Milan, Italy from January 2010 to November 2017. The patients were divided into two groups: patients that underwent therapy with DAAs and patients that underwent HCV treatment with P/R. Patients were assessed by a dermatologist for psoriasis symptoms, collecting Psoriasis Area Severity Index(PASI) scores and the Dermatology Quality of Life Index(DLQI). PASI and DLQI scores were evaluated 24 wk after the end of HCV treatment and were assumed as an outcome of the progression of psoriasis. Switching to a different b DMARD was considered as an inadequate response to biological therapy. The dropout of HCV therapy and sustained virological response(SVR) were considered as outcomes of HCV therapy.RESULTS Fifty-nine psoriatic patients in biological therapy underwent antiviral therapy for CHC. Of this, 27 patients were treated with DAAs and 32 with P/R. After 24 wk post treatment, the DLQI and the PASI scores were significantly lower(P < 0.001 and P < 0.005, respectively) in the DAAs group compared with P/R group. None of the patients in the DAAs group(0/27) compared to 8 patients of the P/R group(8/32) needed a shift in biological treatment.CONCLUSION DAAs seem to be more effective and safe than P/R in HCV-positive psoriatic patients on biological treatment. Fewer dermatological adverse events may be due to interferon-free therapy. | Giovanni Damiani Chiara Franchi Paolo Pigatto Andrea Altomare Alessia Pacifico Stephen Petrou Sebastiano Leone Maria Caterina Pace Marco Fiore | 2018 | World Journal of Hepatology2018，10，2： | 1 |
| 3 | Time to Readiness for Discharge is a Valid and Reliable Measure of Short-Term Recovery After Colorectal Surgery显示文摘 | Julio F. Fiore Ian G. Faragher Andrea Bialocerkowski Laura Browning Linda Denehy | 2013 | World Journal of Surgery2013，，12： | 1 |
| 4 | To metabolomics and beyond:a technological portfolio to investigate cancer metabolism显示文摘Tumour cells have exquisite flexibility in reprogramming their metabolism in order to support tumour initiation, progression,metastasis and resistance to therapies. These reprogrammed activities include a complete rewiring of the bioenergetic, biosyntheticand redox status to sustain the increased energetic demand of the cells. Over the last decades, the cancer metabolism field hasseen an explosion of new biochemical technologies giving more tools than ever before to navigate this complexity. Within a cell ora tissue, the metabolites constitute the direct signature of the molecular phenotype and thus their profiling has concrete clinicalapplications in oncology. Metabolomics and fluxomics, are key technological approaches that mainly revolutionized the fieldenabling researchers to have both a qualitative and mechanistic model of the biochemical activities in cancer. Furthermore, theupgrade from bulk to single-cell analysis technologies provided unprecedented opportunity to investigate cancer biology at cellularresolution allowing an in depth quantitative analysis of complex and heterogenous diseases. More recently, the advent offunctional genomic screening allowed the identification of molecular pathways, cellular processes, biomarkers and noveltherapeutic targets that in concert with other technologies allow patient stratification and identification of new treatmentregimens. This review is intended to be a guide for researchers to cancer metabolism, highlighting current and emergingtechnologies, emphasizing advantages, disadvantages and applications with the potential of leading the development ofinnovative anti-cancer therapies. | Federica Danzi Raffaella Pacchiana Andrea Mafficini Maria TScupoli Aldo Scarpa Massimo Donadelli Alessandra Fiore | 2023 | Signal Transduction and Targeted Therapy2023，8，4： | 1 |
| 5 | May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis?显示文摘AIM To evaluate mucosal baseline m RNA expression of tissue transglutaminase 2(t TG2), interferon gamma(IFNγ), toll-like receptor 2(TLR2) and Myeloid Differentiation factor 88(MyD 88) in patients with microscopic enteritis(ME).METHODS We retrospectively enrolled 89 patients with ME of different etiology, which was defined within a 2-year mean period of follow-up. Baseline histological examination was performed on Hematoxylin-Eosin stained sections and CD3 lymphocyte immunohistochemistry was used for intraepithelial lymphocyte count(IELs). ME was defined according to the criteria of Bucharest Consensus Conference. For each patient, formalin embedded biopsy samples of the duodenum referred to the period of ME diagnosis were retrieved. Real-time polymerase chain reaction(RT-PCR) was used to detect the amount of mR NA coding for tT G2, IFNγ, TLR2 and My D88, and the quantity was expressed as fold change compared to controls. Control group was represented by duodenal normal specimens from 15 healthy subjects undergoing endoscopy for functional symptoms. Comparisons among continuous variables were performed by One way analysis of variance(ANOVA) and Bonferroni’s test. The χ~2 test was used for categorical variables. Pearson’s test was used to evaluate correlations. Receiver operating curves were drawn for all four markers to estimate sensitivity and specificity in discriminating the development of CD and GS.RESULTS After a period of follow up of 21.7 ± 11.7 mo, the following diagnoses were achieved: gluten related disorders in 48 subjects(31 CD; 17 GS) and non-gluten related ones in 41(29 Irritable Bowel Syndrome- IBS; 12 Others). CD patients had the highest tT G2 levels(8.3 ± 4.5). The ANOVA plus Bonferroni analysis showed that CD > Other ME > GS = IBS > negative controls. A cut off value of 2.258 was able to discriminate between CD and GS with a sensitivity of 52.94% and a specificity of 87.1%. Additionally, CD patients had the highest IFNγ levels(8.5 ± 4.1). ANOVA plus Bonferroni demonstrated CD > Other ME > GS = IBS > negative controls. A cut off of 1.853 was able to differentiate CD and GS with a sensitivity of 47.06% and a specificity of 96.77%. Patients with non gluten-related causes of ME exhibited the highest TLR2 levels(6.1 ± 1.9) as follows: Other ME > CD = GS = IBS > negative controls. TLR2 was unable to discriminate CD from GS. Patients with CD overexpressed MyD 88 levels similarly to non gluten-related causes of DL(7.8 ± 4.9 and 6.7 ± 2.9), thus CD = Other ME > GS = IBS > negative controls. A cut off of 3.722 was able to differentiate CD from GS with a sensitivity of 52.94% and a specificity of 74.19%. IELs count(15-25 and more than 25/100 enterocytes) strongly correlated with mR NA levels of all tested molecules(P < 0.0001).CONCLUSION Our results confirm that a single marker is unable to predict a discrimination among ME underlying conditions as well as between CD and GS. Mucosal high levels of t TG and IFNγ m RNA may predict the development of CD more than GS with high specificity, despite an expected low sensitivity. TLR2 does not discriminate the development of CD from GS. My D88 levels indicate that intestinal permeability is more increased when a severe intestinal damage underlies ME in both gluten related and unrelated conditions. Therefore, the results of the present paper do not seem to show a clear translational value. | Giuseppe Losurdo Floriana Giorgio Domenico Piscitelli Lucia Montenegro Claudia Covelli Maria Grazia Fiore Antonio Giangaspero Andrea Iannone Mariabeatrice Principi Annacinzia Amoruso Michele Barone Alfredo Di Leo Enzo Ierardi | 2016 | World Journal of Gastroenterology2016，22，35： | 1 |
| 6 | Modification of cardiac function in cirrhotic patients with and without ascites显示文摘 | Valentina Valeriano Stefania Funaro Raffaella Lionetti Oliviero Riggio Giovanna Pulcinelli Pierluigi Fiore Andrea Masini Stefano De Castro Manuela Merli | 2000 | The American Journal of Gastroenterology2000，，11： | 1 |
| 7 | Early social enrichment shapes soci al behavi or and nerve growth factor and brain-derived neu- rotrophic factor levels in the adult mouse brain 显示文摘 | Igor Branchi D'Andrea I Fiore M | 2006 | Biol Psychiatry2006，60，7： | 1 |
| 8 | Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients显示文摘 | Davide Ippolito Davide Fior Pietro Andrea Bonaffini Cristina Capraro Davide Leni Rocco Corso Sandro Sironi | 2014 | European Journal of Radiology2014，，9： | 1 |
| 9 | Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases显示文摘AIM:To assess clinical and endoscopic response to propionyl-L-carnitine hydrochloride(PLC) in colonic inflammatory bowel disease.METHODS:Patients suffering from mild to moderate ulcerative colitis(UC) or Crohn's disease(CD) colitis,with disease activity index(DAI) between 3 and 10 and under stable therapy with oral aminosalicylates,mercaptopurine or azathioprine,for at least 8 wk prior to baseline assessments,were considered suitable for enrollment.Fourteen patients were enrolled to assume PLC 2 g/d(two active tablets twice daily) orally.Clinical-endoscopic and histological activity were assessed by DAI and histological index(HI),respectively,following a colonoscopy performed immediately before and after 4 wk treatment.Clinical response was defined as a lowering of at least 3 points in DAI and clinical remission as a DAI score ≤ 2.Histological response was defined as an improvement of HI of at least 1 point.We used median values for the analysis.Differences pre-and post-treatment were analyzed by Wilcoxon signed rank test.RESULTS:All patients enrolled completed the study.One patient,despite medical advice,took deflazacort 5 d before follow-up colonoscopy examination.No side effects were reported by patients during the trial.After treatment,71%(SE 12%) of patients achieved clinical response,while 64%(SE 13%) obtained remission.Separating UC from CD patients,we observed a clinical response in 60%(SE 16%) and 100%,respectively.Furthermore 60%(SE 16%) of UC patients and 75%(SE 25%) of CD patients were in clinical remission after therapy.The median DAI was 7 [interquartile range(IQR):4-8] before treatment and decreased to 2(IQR:1-3)(P < 0.01) after treatment.Only patients with UC showed a significant reduction of DAI,from a median 6.5(IQR:4-9) before treatment to 2(IQR:1-3) after treatment(P < 0.01).Conversely,in CD patients,although displaying a clear reduction of DAI from 7(IQR:5.5-7.5) before therapy to 1.5(IQR:0.5-2.5) after therapy,differences observed were not significant(P = 0.06).Seventy-nine percent(SE 11%) of patients showed improvement of HI of at least 1 point,while only one CD and two UC patients showed HI stability;none showed HI worsening.Median HI decreased from 1(IQR:1-2),to 0.5(IQR:0-1) at the endoscopic control in the whole population(P < 0.01),while it changed from 1(IQR:1-2) to 0.5(IQR:0-1) in UC patients(P < 0.01) and from 1.5(IQR:1-2) to 0.5(IQR:0-1) in CD patients(P = not significant).The two sample tests of proportions showed no significant differences in clinical and histological response or in clinical remission between UC and CD patients.No side effects were reported during treatment or at 4 wk follow-up visit.CONCLUSION:PLC improves endoscopic and histological activity of mild to moderate UC.Further studies are required to evaluate PLC efficacy in colonic CD patients. | Giuseppe Merra Giovanni Gasbarrini Lucrezia Laterza Marco Pizzoferrato Andrea Poscia Franco Scaldaferri Vincenzo Arena Francesca Fiore Achille Cittadini Alessandro Sgambato Francesco Franceschi Antonio Gasbarrini | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
| 10 | Extracorporeal Shock Wave Therapy for the Treatment of Poststroke Plantar-Flexor Muscles Spasticity: A Prospective Open-Label Study显示文摘 | Andrea Santamato Maria Micello Francesco Panza Francesca Fortunato Giancarlo Logroscino Alessandro Picelli Paolo Manganotti Nicola Smania Pietro Fiore Maurizio Ranieri | 2014 | Topics in Stroke Rehabilitation2014，，1： | 1 |
| 11 | Ultra-subwavelength phase-sensitive Fano-imaging of localized photonic modes显示文摘Photonic and plasmonic devices rely on nanoscale control of the local density of optical states(LDOS)in dielectric and metallic environments.The tremendous progress in designing and tailoring the electric LDOS of nano-resonators requires an investigation tool that is able to access the detailed features of the optical localized resonant modes with deep-subwavelength spatial resolution.This scenario has motivated the development of different nanoscale imaging techniques.Here,we prove that a technique involving the combination of scanning near-field optical microscopy with resonant scattering spectroscopy enables imaging the electric LDOS in nano-resonators with outstanding spatial resolution(λ/19)by means of a pure optical method based on light scattering.Using this technique,we investigate the properties of photonic crystal nanocavities,demonstrating that the resonant modes appear as characteristic Fano line shapes,which arise from interference.Therefore,by monitoring the spatial variation of the Fano line shape,we locally measure the phase modulation of the resonant modes without the need of external heterodyne detection.This novel,deep-subwavelength imaging method allows us to access both the intensity and the phase modulation of localized electric fields.Finally,this technique could be implemented on any type of platform,being particularly appealing for those based on non-optically active material,such as silicon,glass,polymers,or metals. | Niccolo Caselli Francesca Intonti Federico La China Francesco Riboli Annamaria Gerardino Wei Bao Alexander Weber Bargioni Lianhe Li Edmund H Linfield Francesco Pagliano Andrea Fiore Massimo Gurioli | 2015 | Light(Science & Applications)2015，4，1： | 0 |
| 12 | Reversal of IgM deficiency following a gluten-free diet in seronegative celiac disease显示文摘Selective Ig M deficiency(s IGMD)is very rare;it may be associated with celiac disease(CD).We present the case of an 18-year-old man with s IGMD masking seronegative CD.Symptoms included abdominal pain,diarrhea and weight loss.Laboratory tests showed reduced Ig M,DQ2-HLA and negative anti-transglutaminase.Villous atrophy and diffuse immature lymphocytes were observed at histology.Tissue transglutaminase m RNA mucosal levels showed a 6-fold increase.The patient was treated with a gluten-free diet(GFD)and six months later the symptoms had disappeared,the villous architecture was restored and mucosal tissue transglutaminase m RNA was comparable to that of healthy subjects.After 1 year of GFD,a complete restoration of normal Ig M values was observed and duodenal biopsy showed a reduction of immature lymphocytes and normal appearance of mature immune cells. | Lucia Montenegro Domenico Piscitelli Floriana Giorgio Claudia Covelli Maria Grazia Fiore Giuseppe Losurdo Andrea Iannone Enzo Ierardi Alfredo Di Leo Mariabeatrice Principi | 2014 | World Journal of Gastroenterology2014，20，46： | 0 |
| 13 | Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy:A retrospective study显示文摘BACKGROUND Sarcopenia is a condition characterized by decreased skeletal muscle mass due to physiological ageing or to a concomitant disease such as neoplasia.In cancer patients,a low lean body mass is suggested to be a negative prognostic factor for survival and for the development of dose-limiting chemotherapy toxicities irrespective of disease stage.AIM To evaluate the prognostic role of sarcopenia in patients with metastatic colorectal cancer(mCRC)undergoing first-line chemotherapy.METHODS Our retrospective analysis included 56 mCRC patients who received first-line chemotherapy from 2014 to 2017 at the Medical Oncology Unit of our hospital.Computerized scans were performed before starting chemotherapy and at the first disease reassessment.Sarcopenia was assessed using the skeletal mass index=muscle area in cm^(2)/(height in m^(2))calculated at the L3 vertebra.Overall survival and objective response rate were evaluated.Toxicities were analyzed during the first four cycles of therapy and graded according to Common Terminology Criteria for Adverse Events version 4.0.A loss of skeletal muscle mass≥5%was considered indicative of deterioration in muscle condition.RESULTS Median age was 67 years and 35.7%of patients were≥70 years old.Fourteen patients(25%)were sarcopenic at baseline computed tomography(CT)scan(7/33 men;7/23 women);5/14 sarcopenic patients were≥70 years old.Median followup was 26.8 mo(3.8-66.8 mo)and median overall survival was 27.2 mo(95%CI:23.3-37.3).Sarcopenia was not correlated to overall survival(P=0.362),to higher toxicities reported during the first 4 cycles of chemotherapy(P=1.0)or to response to treatment(P=0.221).At the first disease reassessment,a skeletal muscle loss(SML)≥5%was found in 17 patients(30.3%)3 of whom were already sarcopenic at baseline CT scan,while 7 patients became sarcopenic.SML was not correlated to overall survival(P=0.961).No statistically significant correlation was found between baseline sarcopenia and age(P=1.0),body mass index(P=0.728),stage at diagnosis(P=0.355)or neutrophil/lymphocyte ratio(P=0.751).CONCLUSION Neither baseline sarcopenia nor SML affected survival.In addition,baseline sarcopenia was not related to worse treatment toxicity.However,these results must be interpreted with caution due to the limited sample size. | Chiara Maddalena Andrea Ponsiglione Luigi Camera Lidia Santarpia Fabrizio Pasanisi Dario Bruzzese Camilla Panico Giovanni Fiore Simona Camardella Tolomeo Caramia Alessia Farinaro Sabino De Placido Chiara Carlomagno | 2021 | World Journal of Clinical Oncology2021，12，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员